It’s Time To Focus On The Long Run With Mirum Pharmaceuticals Inc. (MIRM) stock

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) closed the day trading at $21.46 up 0.99% from the previous closing price of $21.25. In other words, the price has increased by $+0.21 from its previous closing price. On the day, 519176 shares were traded. MIRM stock price reached its highest trading level at $21.94 during the session, while it also had its lowest trading level at $20.70.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Ratios:

For a better understanding of MIRM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on September 01, 2022, initiated with a Buy rating and assigned the stock a target price of $38.

On September 20, 2021, JP Morgan started tracking the stock assigning a Overweight rating and target price of $30.

Raymond James Upgraded its Outperform to Strong Buy on August 07, 2020, whereas the target price for the stock was revised from $28 to $48.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 15 when O’Donnell Niall sold 93,770 shares for $19.69 per share. The transaction valued at 1,846,022 led to the insider holds 1,621,118 shares of the business.

O’Donnell Niall sold 32,109 shares of MIRM for $629,423 on Nov 14. The Director now owns 1,714,888 shares after completing the transaction at $19.60 per share. On Nov 11, another insider, O’Donnell Niall, who serves as the Director of the company, sold 174,121 shares for $19.99 each. As a result, the insider received 3,481,410 and left with 1,746,997 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 15.88 while its Price-to-Book (P/B) ratio in mrq is 4.42.

Stock Price History:

Over the past 52 weeks, MIRM has reached a high of $30.55, while it has fallen to a 52-week low of $16.07. The 50-Day Moving Average of the stock is 19.46, while the 200-Day Moving Average is calculated to be 22.36.

Shares Statistics:

Over the past 3-months, MIRM traded about 350.68K shares per day on average, while over the past 10 days, MIRM traded about 415.51k shares per day. A total of 36.87M shares are outstanding, with a floating share count of 35.24M. Insiders hold about 0.70% of the company’s shares, while institutions hold 94.80% stake in the company. Shares short for MIRM as of Oct 13, 2022 were 2.05M with a Short Ratio of 1.05M, compared to 2.36M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.58% and a Short% of Float of 8.96%.

Earnings Estimates

Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$1.07 for the current quarter, with a high estimate of -$0.94 and a low estimate of -$1.21, while EPS last year was -$1.55. The consensus estimate for the next quarter is -$1.1, with high estimates of -$0.77 and low estimates of -$1.67.

Analysts are recommending an EPS of between -$2.2 and -$4.73 for the fiscal current year, implying an average EPS of -$3.96. EPS for the following year is -$2.94, with 8 analysts recommending between -$1.57 and -$3.6.

Revenue Estimates

6 analysts predict $20.81M in revenue for the current quarter. It ranges from a high estimate of $22.9M to a low estimate of $19.13M. As of the current estimate, Mirum Pharmaceuticals Inc.’s year-ago sales were $5M, an estimated increase of 316.20% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $23.98M, an increase of 664.20% over than the figure of $316.20% in the same quarter last year. There is a high estimate of $25.9M for the next quarter, whereas the lowest estimate is $21.58M.

A total of 7 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $79.2M, while the lowest revenue estimate was $72.76M, resulting in an average revenue estimate of $75.56M. In the same quarter a year ago, actual revenue was $19.14M, up 294.80% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $149.21M in the next fiscal year. The high estimate is $185.6M and the low estimate is $120.1M. The average revenue growth estimate for next year is up 97.50% from the average revenue estimate for this year.